Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2014 Archives
Philadelphia, PA – December 18, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its... More |
Talented Leader Brings Senior Level Operations, Global Experience Philadelphia, PA – December 5, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Michael J. Bogda as president, effective December 1, 2014. Arthur Bedrosian... More |
Philadelphia, PA – December 2, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday,... More |
Ernest Sabo, Vice President of Regulatory Affairs and Chief Compliance Officer, To Retire After a Distinguished 45-year Career, 10 years at Lannett Philadelphia, PA – November 17, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that Ernest J. Sabo, the company’s vice president of regulatory affairs and chief compliance... More |
Philadelphia, PA – November 3, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has completed its cGMP compliance inspection of... More |
Company Raises Outlook for Fiscal 2015 Philadelphia, PA – November 3, 2014 – Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 first quarter ended September 30, 2014.\ For the fiscal... More |
Philadelphia, PA – October 29, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Credit-Suisse 2014 Healthcare Conference on Tuesday,... More |
Philadelphia, PA – October 29, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its... More |
Company to Report Full Financial Results, Host Conference Call on November 3 Philadelphia, PA – October 23, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2015 first quarter net sales of approximately $93 million and... More |
Philadelphia, PA – September 30, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the class action lawsuit filed against the company and certain officers in the United... More |
Strong Sales of Digoxin Continue; Company Reaffirms Fiscal 2015 Guidance Philadelphia, PA – September 22, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution... More |
Company Concludes It Is in Compliance with Applicable Laws and Regulations Philadelphia, PA – September 16, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that upon receipt of the subpoena from the State of Connecticut Office of the Attorney General... More |
Philadelphia, PA – September 10, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its... More |
Philadelphia, PA – August 28, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Morgan Stanley Global Healthcare Conference 2014 on Monday,... More |
Company Reports Seventh Consecutive Quarter of Record Net Sales Totaling $81 Million, Gross Margin of 69%, EPS of $0.64; Guides to Strong Fiscal 2015 Philadelphia, PA – August 27, 2014 – Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2014 fourth quarter and full year ended June 30, 2014. For the... More |
Philadelphia, PA – August 20, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and... More |
Philadelphia, PA – August 20, 2014 – Lannett Company, Inc. (NYSE: LCI) today commented on the utilization of Digoxin, following a recently published abstract in the Journal of the... More |
Company Expects To Report Full Financial Results, Host Conference Call On Wednesday, August 27th Preliminary Fiscal 2014 Financial Results: Fourth quarter: Net sales of $81 million; EPS between $0.60 and $0.64 Full year: Net sales of $274 million; Adjusted EPS between $1.94 and $1.98... More |
Philadelphia, PA – August 5, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday,... More |
Philadelphia, PA – August 4, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated... More |
Philadelphia, PA – July 17, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has signed an agreement with Symplmed, Inc. to be the exclusive distributor in the United... More |
Philadelphia, PA – July 16, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received interrogatories and subpoena from the State of Connecticut Office of the... More |
Philadelphia, PA – June 16, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated... More |
Philadelphia, PA – June 2, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will be added to the S&P SmallCap 600 Index today, after the close of trading.... More |
Philadelphia, PA – May 12, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into distribution and contract manufacturing services agreements with Sunshine... More |
| 1-25 26-33 |